Quality of Life in Schizophrenic Patients

Sponsor
AstraZeneca (Industry)
Overall Status
Completed
CT.gov ID
NCT00597168
Collaborator
(none)
124
46
24
2.7
0.1

Study Details

Study Description

Brief Summary

This is a non-interventional study evaluating quality of life in schizophrenic patients treated with atypical antipsychotics, in the ambulatory setting. This is a 9-month, observational, multicentric prospective study.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    124 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    QUALITY: A Non-interventional Study Evaluating Quality Of Life in Schizophrenic Patients Treated With Atypical Antipsychotics, in the Ambulatory Setting. A 9-month, Observational, Multicentric Prospective Study.
    Study Start Date :
    Oct 1, 2007
    Actual Primary Completion Date :
    Oct 1, 2009
    Actual Study Completion Date :
    Oct 1, 2009

    Outcome Measures

    Primary Outcome Measures

    1. Change from baseline of QOL assessed by the SWN-K after 9 months of treatment with AAPs. [9 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients diagnosed with Schizophrenia treated with atypical antipsychotics (ambulatory patients).

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Research Site Aalst Belgium
    2 Research Site Asse Belgium
    3 Research Site Bertrix Belgium
    4 Research Site Bierbeek Belgium
    5 Research Site Boechout Belgium
    6 Research Site Bon-secours Belgium
    7 Research Site Bruxelles Belgium
    8 Research Site Dendermonde Belgium
    9 Research Site Diest Belgium
    10 Research Site Duffel Belgium
    11 Research Site Eeklo Belgium
    12 Research Site Elsene Belgium
    13 Research Site Embourg Belgium
    14 Research Site Floreffe Belgium
    15 Research Site Gent Belgium
    16 Research Site Halle Belgium
    17 Research Site Henri-Chapelle Belgium
    18 Research Site Herstal Belgium
    19 Research Site Jambes Belgium
    20 Research Site Kortenberg Belgium
    21 Research Site Kortrijk Belgium
    22 Research Site La Louviere Belgium
    23 Research Site Leut Belgium
    24 Research Site Leuven Belgium
    25 Research Site Libramont Belgium
    26 Research Site Liege Belgium
    27 Research Site Lierneux Belgium
    28 Research Site Melle Belgium
    29 Research Site Menen Belgium
    30 Research Site Mol Belgium
    31 Research Site Mons Belgium
    32 Research Site Oostende Belgium
    33 Research Site Ottignies Belgium
    34 Research Site Roeselare Belgium
    35 Research Site Schaerbeek Belgium
    36 Research Site Sint-Kruis (Brugge) Belgium
    37 Research Site Sint-Lambrechts-Woluwe Belgium
    38 Research Site Sint-Michiels Belgium
    39 Research Site Sint-Niklaas Belgium
    40 Research Site Sint-Truiden Belgium
    41 Research Site Sleidinge Belgium
    42 Research Site Tielt Belgium
    43 Research Site Tienen Belgium
    44 Research Site Veurne Belgium
    45 Research Site Waregem Belgium
    46 Research Site Woluwe-Saint-Lambert Belgium

    Sponsors and Collaborators

    • AstraZeneca

    Investigators

    • Principal Investigator: Prof Vermylen, UZ Leuven

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00597168
    Other Study ID Numbers:
    • NIS-NBE-SER-2006/1
    First Posted:
    Jan 17, 2008
    Last Update Posted:
    Jun 9, 2010
    Last Verified:
    Jun 1, 2010
    Keywords provided by , ,
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 9, 2010